Company: DVAX
Filing Date: 2025-05-16
Form Type: DFAN14A
Source: 0001193125-25-121025
Chunk: 0

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-16
Form: DFAN14A
Chunk 0
---
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14A-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box:

| ☐ | Preliminary Proxy Statement |

| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 
 14a-6(e)(2))                                                       |

| ☐ | Definitive Proxy Statement |

| ☒ | Definitive Additional Materials |

| ☐ | Soliciting material Pursuant to §240.14a-12 |

Dynavax Technologies Corporation (Name of Registrant as Specified In Its Charter) DEEP TRACK BIOTECHNOLOGY MASTER FUND, LTD. DEEP TRACK CAPITAL, LP DAVID KROIN BRETT A. ERKMAN JEFFREY S. FARROW MICHAEL MULLETTE DONALD J. SANTEL (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box):

| ☒ | No fee required. |

| ☐ | Fee paid previously with preliminary materials. |

| ☐ | Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. |

Deep Track Capital, LP, a Delaware limited partnership (“Deep Track”), together with the other
participants named herein (collectively the “Participants”), issued the following press release (the “Press Release”) and open letter to shareholders (the “Shareholder Letter,” and, together with the Press Release, the
“Materials”) related to Dynavax Technologies Corporation, a Delaware corporation (the “Company”). Deep Track or its fellow Participants may disseminate the Materials or portions thereof from time to time.

Deep Track Capital Issues Letter to Fellow Dynavax Technologies Shareholders Detailing Critical Issues in Advance of Annual Meeting Cites Evidence That the Company is Not Living Up to Its Potential, As Demonstrated By 26% Year-To- Date Share Price Decline, Underperformance Versus Benchmarks, Precipitous 11% Drop Post-First Quarter Earnings and Fresh 52-WeekLow Highlights Concerns About Dynavax’s Apparent Contentment Regarding Heplisav’s Slowing Market Growth Expressed on Recent Earnings Call Believes